in the fourth quarter and now owns 5,160,043 shares of the specialty pharmaceutical company’s stock.
Very undervalued if this was to occur.
It looks like you have made money Shorting other stocks and not ZIOPHARM Oncology.
I say this from experience and during the past five years have had several big winners, maybe dumb luck as I do not have a PhD in science, with $1 to $3 biotechnology stocks that skyrocketed and I have had disappointments too. The most dramatic was my purchase of Acadia ACAD in 2011 in the mid $1's and hit a 52 Week High about $50, of course on a significant drug breakthrough associated with Parkinson's disease.
This is the biotechnology space story of rags to riches, so in the meantime there is volatility to be expected with high beta company stocks.
I repeat: Sell Zohydro to a large company like Purdue Pharma. They can absorb the cost of sales promotion.
Like energy, i expect a significant recovery rally in the biotechnology space his year.
It is at the broker accessed from my account. I can copy and paste the basic rating in a few hours, but busy right now. There is an in depth report available along with it that would require a link that probablyis not be able to be posted here.